HER2 Low Expression in Primary Male Breast Cancer
Katleen Nobbe,Melanie Erices-Leclercq,Frank Foerster,Robert Förster,Stephan E Baldus,Christian Rudlowski,Lars Schröder,Sabine Lubig
DOI: https://doi.org/10.2147/bctt.s450682
2024-03-29
Breast Cancer Targets and Therapy
Abstract:Katleen Nobbe, 1 Melanie Erices-Leclercq, 1 Frank Foerster, 2, 3 Robert Förster, 4 Stephan E Baldus, 5 Christian Rudlowski, 1, 6 Lars Schröder, 7 Sabine Lubig 1 1 Breast Unit, Lutheran Hospital Bergisch Gladbach, Bergisch Gladbach, Germany; 2 Department of Economical Sciences, University of Applied Sciences, Zwickau, Germany; 3 Outpatient Department of Gynaecological Oncology and Palliative Care, Chemnitz, Germany; 4 Institute for Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland; 5 Institute for Pathology, Cytology and Molecular Pathology, Bergisch Gladbach, Germany; 6 Department of Gynecology, University Hospital Bonn, Bonn, Germany; 7 Department of Gynaecology and Obstetrics, Ketteler Krankenhaus, Offenbach, Germany Correspondence: Christian Rudlowski, Breast Unit, Lutheran Hospital Bergisch Gladbach, Ferrenbergstrasse 24, Bergisch Gladbach, 51465, Germany, Email Purpose: The introduction of HER2-targeting antibody drug conjugates (ADCs) offers new treatment options for female breast cancer patients (FBC) expressing low levels of HER2 (HER2 low). No evidence was found that HER2 low describes a new FBC subtype. There is a lack of studies determining the impact of HER2 low in male breast cancer (MBC). In this study, we evaluate the prevalence of HER2 low in primary MBC and correlate the results with patient characteristics. Patients and Methods: In this study, histological specimens were obtained from 120 male patients diagnosed and treated for primary invasive breast cancer from 1995 to 2022 at Breast Cancer Units in Bergisch Gladbach, Chemnitz, and Zwickau, Germany. HER2 immunostaining and in situ hybridization were performed by central pathology and evaluated based on the ASCO/CAP guidelines. The correlation of expression of HER2 low with tumor biological characteristics and patient outcomes was investigated. Results: Out of all cases, four patients (3.3%) showed HER2 positivity (3+), 39 (32.5%) patients were classified as HER2 low, 7 (5.8%) were HER2 2+ (no amplification), 32 (26.7%) were HER2 1+, and 77 (64.2%) were classified as HER2 zero. Out of 77 HER2 zero cases, 47 tumors (61.0%) showed incomplete staining, with < 10% of tumor cells classified as HER2 ultralow. No statistical correlation between HER2 low and tumor biological characteristics and patients' survival was found. Conclusion: Our findings show a notable, albeit lower, prevalence of HER2 low expression in primary MBC. However, tumors expressing HER2 low do not show specific tumor biological features to define a new breast cancer subtype in MBC. Our results suggest that a significant number of MBC patients could benefit from ADCs, as shown in FBC. Further studies are required to better understand HER2 low breast cancer, both generally and in MBC. Keywords: male breast cancer, HER2 low, prognosis, survival Female breast cancer (FBC) and male breast cancer (MBC) share biological similarities, but significant differences regarding risk factors, prognosis, and response to therapy have been observed. 1 MBC represents a more homogeneous tumor cohort with only minor differences in hormone receptor (HR) expression and HER2 distribution. Usually, MBC is highly HR positive and HER2 negative. 2 HER2 is a transmembrane receptor tyrosine kinase encoded by the ERBB2 gene. 3 It is a potent oncogene associated with a more aggressive tumor behavior. 4 HER2 positivity is a therapeutic target for monoclonal antibody trastuzumab as well as for other anti-HER2 compounds. 5 The introduction of targeted therapies was able to change treatment and prognosis dramatically. 6 Until now HER2 classification followed a binary approach to distinguish between HER2 positive or negative: according to the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP), breast cancer is defined as HER2 positive by protein overexpression score 3+ with immunohistochemistry (IHC) and/or a IHC score 2+ with gene amplification in situ hybridization (ISH). 7 Female as well as male patients who show HER2 positivity are recommended to be treated with antibodies. Patients who were categorized as HER2 negative were not treated with antibodies due to a lack of response. 8 Recent studies shed light on reconsidering the spectrum of HER2 classification: in females more than 60% of HER2 negative breast tumors express low levels of HER2, defined as a score of 1+ by IHC or as an IHC score of 2+ and negative in ISH. 7,9 The development of antibody drug conjugates (ADCs) targeting tumors with lo -Abstract Truncated-